Danaher (NYSE:DHR) said it will be acquiring UK-based biotechnology supplier Abcam (AIM:ABC) for $24 per share or a total enterprise value of about $5.7 billion.
Danaher (NYSE:DHR) beat out rivals who were also bidding for the company including Agilent Technologies (NYSE:A), according to media reports.
Abcam (AIM:ABC) produces a range of laboratory products including proteins, lysates, biochemicals, kits, and assays.
Its acquisition by Danaher (NYSE:DHR) will allow the Washington, DC-based maker of laboratory equipment and other life sciences supplies to expand its services.
The companies said Monday that Abcam (AIM:ABC) is expected to operate as a standalone company and brand within Danaher’s Life Sciences segment.
The all-cash transaction is expected to close in mid-2024, subject to customary conditions.
Danaher said it expects to fund the purchase using cash on hand and proceeds from the issuance of commercial paper.
Danaher’s shares traded modestly higher, up 1% at US$257.98, while Abcam’s Nasdaq-listed shares were down 4.2% to US$22.40 just before the opening bell in New York on Monday.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie